Macquarie Group LTD Immuno Gen, Inc. Transaction History

Macquarie Group LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $15,057 - $21,745	-3,361 Reduced 64.7%	1,834 $25,000
Q1 2021 May 14, 2021	SELL	$6.5 - $10.53 $10,354 - $16,774	-1,593 Reduced 23.47%	5,195 $42,000
Q2 2020 Aug 11, 2020	BUY	$3.32 - $5.34 $22,536 - $36,247	6,788 New	6,788 $31,000
Q4 2019 Feb 14, 2020	SELL	$2.25 - $5.8 $477 - $1,229	-212 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $470 - $718	212 New	212 $1,000
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $630,000 - $1.16 Million	-350,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $723,000 - $1.77 Million	-300,000 Reduced 46.15%	350,000 $949,000
Q3 2018 Nov 15, 2018	SELL	$8.6 - $11.26 $4.15 Million - $5.44 Million	-483,000 Reduced 42.63%	650,000 $6.16 Million
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $28,560 - $36,450	3,000 Added 0.27%	1,133,000 $11 Million
Q1 2018 May 11, 2018	SELL	$6.7 - $12.95 $115,910 - $224,035	-17,300 Reduced 1.51%	1,130,000 $11.9 Million
Q4 2017 Feb 15, 2018	BUY	$5.07 - $7.92 $1.51 Million - $2.35 Million	297,300 Added 34.98%	1,147,300 $7.35 Million
Q3 2017 Nov 08, 2017	BUY	$5.4 - $8.47 $4.59 Million - $7.2 Million	850,000	850,000 $6.5 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.